RGEN — Repligen Corporation

Is RGEN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of November 17, 2026

Repligen Corporation (RGEN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $162.78. The rating moved from Neutral to Oversold on November 10, 2026.

See all oversold Healthcare stocks →

AI analysis

Repligen is well positioned in high‑value bioprocess consumables and services benefiting from durable secular demand in biologics and advanced therapies. The business model features recurring, high‑margin product lines that support cash flow and optionality for targeted M&A or capacity investments. Near‑term market caution and defensive flows could restrain upside over the next few sessions, but medium‑term fundamentals are supported by continued biologics adoption, distributor/channel tailwinds and product differentiation. Primary concerns are revenue lumpy behavior tied to large customers, competitive pressures, and exposure to biotech capex cycles which could delay orders and compress margins. Overall, the outlook is constructive if execution and end‑market demand remain steady; downside scenarios center on order timing, macro‑driven valuation contraction, or material supply/competition headwinds.

Key factors

  • Leading position in bioprocess consumables and chromatography resins with recurring revenue from long product lifecycles
  • Exposure to secular growth in biologics, monoclonal antibodies, cell & gene therapies and increased outsourcing by pharma/biotech
  • High-margin consumables and service mix that supports cash flow generation and potential for accretive M&A
  • Distributor and specialty-channel tailwinds from increased chronic injectable therapy volumes that support downstream demand for bioprocess services
  • Relatively strong balance-sheet flexibility to fund capacity expansion or strategic acquisitions (historical cash generation)

Risks

  • Customer concentration and revenue sensitivity to large biopharma program timing or order lumpy behavior
  • Cyclical capex patterns at drug developers and reduced biotech funding could delay purchases of upstream/downstream equipment
  • Competition from larger OEMs and new entrants in chromatography resins, single‑use systems and bioprocess platforms
  • Supply‑chain disruption or raw‑material cost pressure that could compress margins in the near term
  • Macroeconomic and rate‑sensitive valuation pressure amid defensive market flows that can limit multiple expansion
  • Execution risks around integration of acquisitions or scaling manufacturing capacity

See today's live rating, score and targets

Members see the live hourly rating for RGEN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.